Tomas J. Heyman - 16 Jun 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
16 Jun 2023
Net transactions value
-$770,489
Form type
4
Filing time
21 Jun 2023, 17:54:10 UTC
Previous filing
13 Jun 2023
Next filing
27 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $651,040 +26,000 $25.04 26,000 16 Jun 2023 Direct
transaction AKRO Common Stock Sale $1,421,529 -26,000 -100% $54.67 0 16 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -26,000 -100% $0.000000* 0 16 Jun 2023 Common Stock 26,000 $25.04 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.52 to $54.89, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
F2 The options are vested and currently exercisable.